GlassScriptPhysician profile
Michelle Stiles Deans
NPI 1083042444
$4,380.74
in general payments reported to CMS, 2019-2025
21 companies · $907 in 2025
The $907 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $177 · 2023: $1,059 · 2024: $2,086 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,998 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,997.89 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $685.58 | 2024-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $560.70 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $494.92 | 2021-2025 | Farxiga, Wainua |
| Biosense Webster, INC. | $490.54 | 2023-2024 | Carto 3, Qdot Micro Catheter |
| Edwards Lifesciences Corporation | $321.19 | 2022-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $298.39 | 2022-2025 | Aurora Ev-Icd Mri Surescan, Linq II |
| Impulse Dynamics (USA) INC. | $220.31 | 2023-2024 | Optimizer, Optimizer |
| Sanofi-Aventis U.S. LLC | $213.82 | 2023-2024 | |
| Abbott Laboratories | $200.92 | 2023-2024 | Tendril, Merlin@Home |
| Atricure, INC. | $166.51 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Pfizer INC. | $132.31 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.99 | 2023-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $101.95 | 2023-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $90.60 | 2023-2025 | |
| Scpharmaceuticals INC. | $74.05 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $71.25 | 2023-2024 | Xarelto |
| Bridgebio Pharma, INC. | $50.36 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $35.00 | 2023 | Verquvo, Belsomra |
| Alnylam Pharmaceuticals INC. | $32.02 | 2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $17.32 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Deans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.